Status: Recruiting
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Pathos AI, Inc.Updated: Jun 10, 2026Locations: 18
Eligibility criteria
≥18 years of age [+2]
Current or prior evidence of any small cell or neuroendocrine histology on the m... [+6]